Actinium Pharmaceuticals vs Lisata Therapeutics
ATNM and LSTA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ATNM and LSTA compare
Actinium Pharmaceuticals is the larger company, worth 4.7 times as much as Lisata Therapeutics ($51.6M against $10.9M).
Actinium Pharmaceuticals scores higher on the StockData Score (10 against 6 for Lisata Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ATNM | LSTA |
|---|---|---|
| Size and price | ||
| Market cap | $51.6M | $10.9M |
| Share price | $1.64 | $1.21 |
| Change, 1 year | 26.2% | −44.0% |
| Change, 5 years | −78.5% | −92.2% |
| Beta (5Y) | 1.10 | 0.74 |
| Employees | 25 | 21 |
| StockData Score | ||
| Total score | 10 (better) | 6 |
| Valuation score | 4 (better) | 1 |
| Growth score | 0 | 0 |
| Performance score | 1 (better) | 0 |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 4.6× | – |
| P/S | – | 109× |
| P/B | 1.7× | 1.4× (better) |
| EV/EBITDA | 1.5× | – |
| FCF yield | – | −199% |
| Fair value | $7.86 | – |
| Margin of safety | 79.1% | – |
| Growth | ||
| Revenue growth (TTM) | – | −90.7% |
| Profitability | ||
| Operating margin | – | −22043% |
| Net margin | – | −17159% |
| FCF margin | – | −21662% |
| Return on equity | 45.9% (better) | −137% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 4.08 | 14.09 (better) |
| Altman Z-score | −8.73 | −0.75 (better) |
| Piotroski F-score | 2 (better) | 1 |
| Dividends and buybacks | ||
| Buyback yield | – | −2.1% |
| Shareholder yield | 0.00% (better) | −2.1% |
| Ownership | ||
| Held by institutions | 16.8% | 12.1% |
| Held by insiders | 5.9% | 11.6% |
| Short interest, % of float | 2.0% | 0.43% |
Go deeper
- ATNM stock overview
- ATNM income statement
- ATNM valuation and score
- LSTA stock overview
- LSTA income statement
- LSTA valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.